Product Description

Scapho 150 mg Injection contains secukinumab, a fully human monoclonal antibody that selectively targets and neutralizes interleukin-17A (IL-17A), a key pro-inflammatory cytokine involved in the pathogenesis of psoriasis and other autoimmune conditions. By blocking IL-17A, Scapho reduces excessive immune responses, thereby decreasing skin plaques, joint inflammation, and spinal stiffness. It is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, and ankylosing spondylitis. Administered through subcutaneous injection, Scapho offers a convenient monthly dosing regimen to maintain long-term disease control.